Exemestane: irreversible aromatase inhibition, and what that changes

Anastrozole competes with the substrate for the enzyme; exemestane destroys the enzyme. That difference sounds academic and has one very practical consequence: an overshoot here does not resolve when the drug clears.

Inactivation, not competition

Established clinical use Aromatase converts androgens to oestrogens. Anastrozole and letrozole are non-steroidal inhibitors that bind the enzyme reversibly and compete with the natural substrate: remove the drug and the enzyme works again. Exemestane is a steroidal analogue of the substrate itself, and it binds irreversibly — the enzyme is permanently inactivated, and activity returns only as the cell synthesises new enzyme.

The half-life of the drug is therefore not the duration of the effect. The app models about a day for the molecule; recovery of aromatase activity is measured in days beyond that, and depends on protein turnover rather than clearance. Anyone reasoning about exemestane from its half-life is reasoning about the wrong quantity.

The practical consequence is asymmetric. Suppressing too little is easy to correct. Suppressing too much is not corrected by stopping and waiting a day, which is exactly the situation an aromatase inhibitor should be least likely to create. That is the main argument for treating exemestane as the less forgiving of the two.

It is a steroid, and that cuts both ways

Off-label or community practice Being a steroidal molecule gives exemestane properties anastrozole does not have. It is weakly androgenic itself and is metabolised to 17-hydroxyexemestane, which is more so. That is offered as an advantage — a lipid profile that some argue holds up better than with the non-steroidal inhibitors — and it is also the source of the androgenic effects the app’s own drawbacks list mentions. Both follow from the same fact.

The two drugs are not dose-equivalent and results with one do not transfer to the other. Milligram comparisons between them are meaningless: they inhibit the same enzyme by mechanisms with different kinetics and different recovery. A schedule copied across from anastrozole is a guess.

Everything the anastrozole page says still applies

Established clinical use Oestrogen in men is required for bone mineralisation, contributes to libido and erectile function, and affects lipid handling. Suppressing it toward zero is not a conservative choice, and the symptoms of too little overlap almost entirely with the symptoms of too much — low libido, flat mood, joint aches. Distinguishing them requires a measurement, and it has to be a sensitive assay: standard immunoassay estradiol is unreliable at male concentrations. The estradiol assay page covers why.

Off-label or community practice Use in hormone therapy is off-label; the approval is in oncology, where the goal is maximal suppression in a completely different population. The direction of practice over the last decade has been away from routine or prophylactic aromatase inhibition and toward adjusting the testosterone protocol first. The anastrozole page covers that argument in full, and it applies here with the added caution that this drug is harder to walk back.

Which of these applies to a particular person, and at what amount, is a decision made from a sensitive-assay result by a prescriber. Anything on the drawbacks list below that you are experiencing belongs in front of them rather than being managed against a page.

How long one dose lasts

Try other intervals on the half-life and steady-state calculator, which runs the same function against whatever cadence you type.

The dosing rows the app records

Established clinical use Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Exemestane, verbatim. The analytes in it that have a page here are linked; those pages cover what each one measures, which assay produced it and how to read a trend.

• Sensitive versus standard estradiol
• Total testosterone
• Free versus total testosterone, and the three ways labs get the free number

Drawbacks and risks the app records

From the app’s own entry. The first item is the one that distinguishes this drug from the alternative, and it is a reason for more caution rather than less.

• Irreversible mechanism means overcorrection is harder to reverse
• Steroid-based — some androgenic sides possible
• Joint pain and hot flashes with over-suppression
• More expensive than anastrozole
• Still requires bloodwork guidance
• Bone density concerns with long-term over-suppression

Interaction rules that name Exemestane

From the app’s interaction data, filtered so no rule naming a compound this site does not publish appears. Not exhaustive, and not a safety clearance: a combination that is not listed is one nobody has documented here, which is not the same as one that is fine. The combination checker has the rest.

Questions people actually ask

Is exemestane better than anastrozole for men?

It has a different mechanism, a steroidal structure and arguments made for its lipid profile. It is also irreversible, which makes over-suppression harder to undo. "Better" depends on which of those matters more for a given person, and that is a prescribing judgement rather than a settled answer.

Can it be dosed like anastrozole?

No. They are not dose-equivalent, and the kinetics of recovery differ completely — one resolves as the drug clears, the other as new enzyme is made. Converting a schedule between them by milligrams has no basis.

What does over-suppression look like?

A sensitive-assay estradiol below the lower reference limit, usually with joint discomfort, low libido and low mood that began after the inhibitor rather than before it. The temporal relationship is the informative part, which is the argument for recording when a change was made.

Why is the effect longer than the half-life?

Because the enzyme is inactivated rather than blocked. Clearing the drug does not restore activity; synthesising new aromatase does, and that runs on protein turnover rather than pharmacokinetics.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.